Breast Cancer Research and Treatment

, Volume 134, Issue 2, pp 881–888 | Cite as

NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup

  • Michael Retsky
  • Rick Rogers
  • Romano Demicheli
  • William JM Hrushesky
  • Isaac Gukas
  • Jayant S. Vaidya
  • Michael Baum
  • Patrice Forget
  • Marc DeKock
  • Katharina Pachmann
Brief Report

Abstract

To explain a bimodal relapse hazard among early stage breast cancer patients treated by mastectomy we postulated that relapses within 4 years of surgery resulted from something that happened at about the time of surgery to provoke sudden exits from dormant phases to active growth. Relapses at 10 months appeared to be surgery-induced angiogenesis of dormant avascular micrometastases. Another relapse mode with peak about 30 months corresponded to sudden growth from a single cell. Late relapses were not synchronized to surgery. This hypothesis could explain a wide variety of breast cancer observations. We have been looking for new data that might provide more insight concerning the various relapse modes. Retrospective data reported in June 2010 study of 327 consecutive patients compared various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Follow-up was average 27.3 months with range 13–44 months. Updated hazard as of September 2011 for this series is now presented. NSAID ketorolac, a common analgesic used in surgery, is associated with far superior disease-free survival in the first few years after surgery. The expected prominent early relapse events are all but absent. In the 9–18 month period, there is fivefold reduction in relapses. If this observation holds up to further scrutiny, it could mean that the simple use of this safe and effective anti-inflammatory agent at surgery might eliminate most early relapses. Transient systemic inflammation accompanying surgery could be part of the metastatic tumor seeding process and could have been effectively blocked by perioperative anti-inflammatory agents. In addition, antiangiogenic properties of NSAIDs could also play a role. Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses.

Keywords

Early relapse Analgesia  Ketorolac Inflammation NSAID Triple negative breast cancer Computer simulation 

Abbreviations

NSAID

Nonsteroid anti-inflammatory drug

CEBH

Commission d’Ethique Biomédicale Hospitalo-Facultaire de l’Université catholique de Louvain

CTC

Circulating tumor cells

TNBC

Triple negative breast cancer

IL-6

Interleukin-6

Notes

Acknowledgments

This study was supported in part by Grant no. 100484 from Susan G. Komen for the Cure. The funding organization played no role in design of study, collection and interpretation of data, decision to publish or writing of paper. Brussels data updated September 2011 shown in Fig. 6 were provided by Sarah Amar and analyzed by Romano Demicheli.

Conflict of interest

Michael Retsky has a patent pending for treatment of early stage cancer and is on the Board of Directors of the Colon Cancer Alliance (www.ccalliance.org). Authors declare no other competing interests.

References

  1. 1.
    Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I (2010) Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth? Cancers 2:305–337. http://www.mdpi.com/2072-6694/2/2/305/ Google Scholar
  2. 2.
    Ariel I (1994) A historical review of breast cancer treatment. In: Johnson H, Wise L (eds) Breast cancer: controversies in management. Futura, Armonk, NYGoogle Scholar
  3. 3.
    Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, De Kock M (2010) Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 110(6):1630–1635. http://www.ncbi.nlm.nih.gov/pubmed/20435950 Google Scholar
  4. 4.
    Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M (2010) Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg 110(6):1636–1643PubMedCrossRefGoogle Scholar
  5. 5.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet, 0099-5355 357: 9255Google Scholar
  6. 6.
    Keibel A, Singh V, Sharma MC (2009) Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15(17):1949–1955 ReviewPubMedCrossRefGoogle Scholar
  7. 7.
    Pascual M, Alonso S, Parés D, Courtier R, Gil MJ, Grande L, Pera M (2011) Randomized clinical trial comparing inflammatory and angiogenic response after open versus laparoscopic curative resection for colonic cancer. Br J Surg 98(1):50–59PubMedCrossRefGoogle Scholar
  8. 8.
    Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33(4):335–351 ReviewPubMedCrossRefGoogle Scholar
  9. 9.
    Jones FS, Rous P (1914) On the cause of the localization of secondary tumors at points of injury. J Exp Med 20(4):404–412PubMedCrossRefGoogle Scholar
  10. 10.
    DerHagopian RP, Sugarbaker EV, Ketcham A (1978) Inflammatory oncotaxis. JAMA 240(4):374–375PubMedCrossRefGoogle Scholar
  11. 11.
    El Saghir NS, Elhajj II, Geara FB, Hourani MH (2005) Trauma-associated growth of suspected dormant micrometastasis. BMC Cancer 5:94PubMedCrossRefGoogle Scholar
  12. 12.
    Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L, Aly T, Wanebo K, Chan ED (2011) Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol 44(5):591–596PubMedCrossRefGoogle Scholar
  13. 13.
    Martins-Green M, Boudreau N, Bissell MJ (1994) Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 54(16):4334–4341PubMedGoogle Scholar
  14. 14.
    Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2(6):351–365PubMedCrossRefGoogle Scholar
  15. 15.
    Zhe X, Cher ML, Bonfil RD (2011) Circulating tumor cells: finding the needle in the haystack. Am J Can Res 1(6):740–751Google Scholar
  16. 16.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other tissues. Nature 407:249–257PubMedCrossRefGoogle Scholar
  17. 17.
    Butler JM, Kobayashi H, Rafii S (2010) Instructive role of the vascular niche in promoting tumor growth and tissue repair by angiocrine factors. Nat Rev Cancer 10:138–146PubMedCrossRefGoogle Scholar
  18. 18.
    Favaro E, Amadori A, Indraccolo S (2008) Cellular interaction in the vascular niche: implications in the regulation of tumor dormancy. APMIS 116:648–659PubMedCrossRefGoogle Scholar
  19. 19.
    Kavanagh DP, Kalia N (2011) Hematopoietic stem cell homing to injured tissues. Stem Cell Rev 7:672–682PubMedCrossRefGoogle Scholar
  20. 20.
    Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C (2011) Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol 55(4–5):527–534PubMedCrossRefGoogle Scholar
  21. 21.
    Takemoto Y, Li TS, Kubo M, Ohshima M, Ueda K, Harada E, Enoki T, Okamoto M, Mizukami Y, Murata T, Hamano K (2011) Operative injury accelerates tumor growth by inducing mobilization and recruitment of bone marrow-derived stem cells. Surgery 149(6):792–800PubMedCrossRefGoogle Scholar
  22. 22.
    Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA (2012) μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116(4):896–902PubMedCrossRefGoogle Scholar
  23. 23.
    Pakneshan P, Birsner AE, Adini I, Becker CM, D’Amato RJ (2008) Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 49(9):3909–3913PubMedCrossRefGoogle Scholar
  24. 24.
    Burke JP, Pestotnik SL, Classen DC, Lloyd JF (1996) Evaluation of the financial impact of ketorolac tromethamine therapy in hospitalized patients. Clin Ther 18(1):197–211PubMedCrossRefGoogle Scholar
  25. 25.
    Pachmann K (2011) Tumor cell seeding during surgery—possible contribution to metastasis formations. Cancers 3:2540–2553CrossRefGoogle Scholar
  26. 26.
    Daskalakis M, Mavroudis D, Sanidas E, Apostolaki S, Askoxylakis I, de Bree E, Georgoulias V, Melissas J (2011) Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. Eur J Surg Oncol 37(5):404–410PubMedCrossRefGoogle Scholar
  27. 27.
    GrØgaard HK, Solheim S, Landsverk KS, Seljeflot I, Hoffmann P, Arnesen H, Ilebekk A (2011) Circulating CD34+ progenitor cells and growth factors in patients treated with PCI for acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest 71:322–329PubMedCrossRefGoogle Scholar
  28. 28.
    Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612PubMedCrossRefGoogle Scholar
  29. 29.
    Wallace TA, Martin DN, Ambs S (2011) Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 32(8):1107–1121PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Michael Retsky
    • 1
    • 5
  • Rick Rogers
    • 1
  • Romano Demicheli
    • 2
  • William JM Hrushesky
    • 3
  • Isaac Gukas
    • 4
  • Jayant S. Vaidya
    • 8
  • Michael Baum
    • 5
  • Patrice Forget
    • 6
  • Marc DeKock
    • 6
  • Katharina Pachmann
    • 7
  1. 1.Harvard School of Public HealthBostonUSA
  2. 2.Scientific DirectorateFondazione IRCCS Istituto Nazionale TumoriMilanItaly
  3. 3.Oncology Analytics, IncPlantationUSA
  4. 4.James Paget University HospitalGreat Yarmouth, NorfolkUIK
  5. 5.Royal Free and UCL Medical School, Centre for Clinical Science and TechnologyUniversity College LondonLondonUK
  6. 6.Department of AnesthesiologyUniversite Catholique de LouvainBrusselsBelgium
  7. 7.Department of Experimental Hematology and Oncology, Clinic for Internal Medicine IIFriedrich Schiller UniversityJenaGermany
  8. 8.Clinical Trials Group of the Division of Surgery and Interventional ScienceUniversity College LondonLondonUK

Personalised recommendations